oral semaglutide launch date FDA Approves as the First Oral GLP-1 Pill? Semaglutide Tablets

J Clin Endocrinol Metab 103(6):22912301

The fact that this pathway exists outside traditional insurance models doesn't make it less legitimate

What stands out: Enforcement focus on mass-marketing, not patient-specific compounding Clear limits on advertising claims, including prohibitions on calling compounded products generic, the same as, or clinically proven Reinforcement of FD&C Act authorities, including misbranding provisions and Section 503A requirements Shift as shortages resolve, removing the legal basis for broad compounding of GLP-1 drugs Expanded compliance tools, including warning letters, seizure, and injunction where violations persist Bottom line: This signals a firmer FDA posture as the GLP-1 market matures, reinforcing long-standing distinctions between FDA-approved drugs and unapproved compounded preparations, particularly when promoted directly to consumers at scale

Prescription weight loss telehealth lets you meet remotely with board-certified obesity physicians to review your history, labs, and BMI, then start a supervised plan with medications, nutrition, and lifestyle coaching